|
Disease-free survival variables
| |
Univariable analysis
|
Multivariable analysis
|
|---|
| |
HR
|
(95% CI)
|
p Value
|
HR
|
(95% CI)
|
p Value
|
|---|
|
Tumor size
|
< 4 cm
|
1
|
0.6
|
1
|
0.2
|
|
≥ 4 cm
|
1.35
|
(0.43 to 4.19)
|
0.43
|
(0.09 to 1.94)
|
|
Nuclear grade
|
1/2
|
1
|
0.9
|
1
|
0.06
|
|
3
|
1
|
(0.28 to 3.56)
|
0.15
|
(0.02 to 1.13)
|
|
ER
|
+
|
1
|
0.03
|
1
|
0.03
|
|
–
|
3.72
|
(1.12 to 12.3)
|
7.53
|
(1.17 to 48.33)
|
|
Nodal involvement
|
–
|
1
|
0.09
|
1
|
0.4
|
|
+
|
5.75
|
(0.74 to 44.2)
|
2.25
|
(0.25 to 19.9)
|
|
FMISO-TBR
|
< 1.48
|
1
|
0.002
|
1
|
0.005
|
|
≥ 1.48
|
5.72
|
(1.83 to 17.82)
|
11.35
|
(2.07 to 62.23)
|
|
Chemotherapy
| |
1
|
0.9
|
N/A
|
|
+
|
368,675.3
|
(5.3E-168 to 25.4E + 177)
|
|
Overall survival variables
| |
Univariable analysis
|
Multivariable analysis
|
| |
HR
|
(95% CI)
|
p Value
|
HR
|
(95% CI)
|
p Value
|
|
Tumor size
|
< 4 cm
|
1
|
0.6
|
1
|
0.7
|
|
≥ 4 cm
|
1.45
|
(0.29 to 7.15)
|
0.71
|
(0.1 to 4.71)
|
|
Nuclear grade
|
1/2
|
1
|
0.9
|
1
|
0.2
|
|
3
|
1.09
|
(1.18 to 6.57)
|
0.21
|
(0.01 to 2.82)
|
|
ER
|
+
|
1
|
0.2
|
1
|
0.1
|
|
–
|
3.03
|
(0.55 to 16.5)
|
10.24
|
(0.57 to 181.96)
|
|
Nodal involvement
|
–
|
1
|
0.9
|
1
|
0.9
|
|
+
|
411,595.95
|
(9.7E-202 to 1.74E + 210)
|
141,679.29
|
(7.17E-223 to 27.97E + 231)
|
|
FMISO-TBR
|
< 1.48
|
1
|
0.06
|
1
|
0.1
|
|
≥ 1.48
|
4.43
|
(0.88 to 22.17)
|
7.59
|
(0.63 to 90.68)
|
|
Chemotherapy
| |
1
|
0.9
|
N/A
|
|
+
|
122,960.7
|
(6.7E-167 to 222.6E + 174)
|
- Abbreviations: FMISO 18F-fluoromisonidazole, ER Estrogen receptor, TBR Tissue-to-blood ratio
